BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai WQ, Zeng LS, Wang LF, Wang YY, Cheng JT, Zhang Y, Han ZW, Zhou Y, Huang SL, Wang XW, Peng XC, Xiang Y, Ma Z, Cui SZ, Xin HW. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Front Oncol 2020;10:1249. [PMID: 32793499 DOI: 10.3389/fonc.2020.01249] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Toffoli EC, Sheikhi A, Lameris R, King LA, van Vliet A, Walcheck B, Verheul HMW, Spanholtz J, Tuynman J, de Gruijl TD, van der Vliet HJ. Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. Cancers (Basel) 2021;13:5446. [PMID: 34771609 DOI: 10.3390/cancers13215446] [Reference Citation Analysis]
2 Zhu J, Yang Q, Xu W. Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics 2021;13:1500. [PMID: 34575576 DOI: 10.3390/pharmaceutics13091500] [Reference Citation Analysis]
3 Sano M, Kaneko MK, Aasano T, Kato Y. Epitope Mapping of an Antihuman EGFR Monoclonal Antibody (EMab-134) Using the REMAP Method. Monoclon Antib Immunodiagn Immunother 2021;40:191-5. [PMID: 34283639 DOI: 10.1089/mab.2021.0014] [Reference Citation Analysis]
4 Rudnik-Jansen I, Howard KA. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. J Control Release 2021;337:248-57. [PMID: 34245786 DOI: 10.1016/j.jconrel.2021.07.007] [Reference Citation Analysis]
5 de Bessa Garcia SA, Araújo M, Pereira T, Freitas R. HOXB7 Overexpression Leads Triple-Negative Breast Cancer Cells to a Less Aggressive Phenotype. Biomedicines 2021;9:515. [PMID: 34063128 DOI: 10.3390/biomedicines9050515] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 You KS, Yi YW, Cho J, Park JS, Seong YS. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:589. [PMID: 34207383 DOI: 10.3390/ph14060589] [Reference Citation Analysis]
7 Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, Shin Y, Rahman MH, Gazi MS, Huda MN, Nam NM, Chung J, Han S, Kim B, Kang I, Ha J, Choe W, Choi TG, Kim SS. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells 2022;11:650. [DOI: 10.3390/cells11040650] [Reference Citation Analysis]
8 Gramespacher JA, Cotton AD, Burroughs PWW, Seiple IB, Wells JA. Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins. ACS Chem Biol 2022. [PMID: 35481357 DOI: 10.1021/acschembio.2c00185] [Reference Citation Analysis]
9 Gong L, Li Y, Cui K, Chen Y, Hong H, Li J, Li D, Yin Y, Wu Z, Huang Z. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy. Small 2021;17:e2103463. [PMID: 34761524 DOI: 10.1002/smll.202103463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Iida M, Mcdaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, Longhurst C, Bruce JY, Hong S, Salgia R, Wheeler DL. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09511-6] [Reference Citation Analysis]
11 Mansour MA, Caputo VS, Aleem E. Highlights on selected growth factors and their receptors as promising anticancer drug targets. Int J Biochem Cell Biol 2021;140:106087. [PMID: 34563698 DOI: 10.1016/j.biocel.2021.106087] [Reference Citation Analysis]
12 Raana G, Shah SQ. Synthesis of 111 In- p -SCN-Bn-DTPA-nimotuzumab and its preclinical evaluation in EGFR positive NSCLC animal model. Radiochimica Acta 2021;109:905-13. [DOI: 10.1515/ract-2021-1054] [Reference Citation Analysis]
13 Pekar L, Klewinghaus D, Arras P, Carrara SC, Harwardt J, Krah S, Yanakieva D, Toleikis L, Smider VV, Kolmar H, Zielonka S. Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity. Front Immunol 2021;12:742418. [PMID: 34759924 DOI: 10.3389/fimmu.2021.742418] [Reference Citation Analysis]
14 Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5471. [PMID: 34771633 DOI: 10.3390/cancers13215471] [Reference Citation Analysis]
15 Huang SL, Wang YM, Wang QY, Feng GG, Wu FQ, Yang LM, Zhang XH, Xin HW. Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy. Front Genet 2021;12:691391. [PMID: 34306031 DOI: 10.3389/fgene.2021.691391] [Reference Citation Analysis]
16 Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci 2022;9:847835. [DOI: 10.3389/fmolb.2022.847835] [Reference Citation Analysis]
17 Huang Y, Ognjenovic J, Karandur D, Miller K, Merk A, Subramaniam S, Kuriyan J. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor. Elife 2021;10:e73218. [PMID: 34846302 DOI: 10.7554/eLife.73218] [Reference Citation Analysis]
18 Iancu G, Serban D, Badiu CD, Tanasescu C, Tudosie MS, Tudor C, Costea DO, Zgura A, Iancu R, Vasile D. Tyrosine kinase inhibitors in breast cancer (Review). Exp Ther Med 2022;23:114. [PMID: 34970337 DOI: 10.3892/etm.2021.11037] [Reference Citation Analysis]
19 Muthusami S, Sabanayagam R, Periyasamy L, Muruganantham B, Park WY. A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer. Int J Biol Macromol 2022;194:179-87. [PMID: 34848237 DOI: 10.1016/j.ijbiomac.2021.11.117] [Reference Citation Analysis]
20 Lin PH, Tseng CL, Cheng YC, Ho CH, Chen SC, Wang Y, Liu E, Issafras H, Jiang W. Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy. Expert Opin Biol Ther 2021;21:1491-507. [PMID: 34632911 DOI: 10.1080/14712598.2021.1988072] [Reference Citation Analysis]
21 Wang MY, Zhou Y, Lai GS, Huang Q, Cai WQ, Han ZW, Wang Y, Ma Z, Wang XW, Xiang Y, Fang SX, Peng XC, Xin HW. DNA barcode to trace the development and differentiation of cord blood stem cells (Review). Mol Med Rep 2021;24:849. [PMID: 34643250 DOI: 10.3892/mmr.2021.12489] [Reference Citation Analysis]
22 Matochko WL, Nelep C, Chen WC, Grauer S, Mcfadden K, Wilson V, Oxenoid K. CellCelector™ as a platform in isolating primary B cells for antibody discovery. Antibody Therapeutics 2022;5:11-7. [DOI: 10.1093/abt/tbab030] [Reference Citation Analysis]